A comprehensive view of Boehringer Ingelheim GmbH. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Eli Lilly, Boehringer Ingelheim announce FDA accepts sNDA for Jardiance empagliflozin, which is being investigated as a treatment to reduce risk of kidney disease progression, cardiovascular death in adults with chronic kidney disease
Published: January 20, 2023 by Eli Lilly & Co.
Eli Lilly and Boehringer Ingelheim report diabetes drug Jardiance empagliflozin significantly reduced average blood sugar in children, adolescents with type 2 diabetes in a late-stage study
Published: December 08, 2022 by SeeNews Pharmaceuticals
US District Court finds nearly 50,000 lawsuits against GSK, Pfizer, Sanofi, Boehringer Ingelheim alleging heartburn drug Zantac causes cancer not backed by sound science; tens of thousands of similar cases are pending in state courts across US
Published: December 07, 2022 by International Business Times
Eli Lilly, Boehringer launch 'Cuide Su Corazón' conversations for Latina women with heart failure; Boehringer reports one in three Latina women have a form of heart disease, yet Latinas are least likely to visit doctor’s office
Published: December 05, 2022 by FiercePharma
German pharma company Boehringer Ingelheim names Lykke Hinsch Gylvin, M.D. as chief medical officer; Dr. Hinsch Gylvin previously served as VP of Global Medical Franchise, head of Neuroscience at Novartis
Published: November 08, 2022 by FiercePharma

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count